The biotech sector has been on a roll lately. The SPDR S&P Biotech ETF ; ;has more than tripled since the start of 2012, compared to “just” a 63% increase in the S&P 500 .Source: Jeff Kubina via Flickr .Are we in a bubble that’s about to pop? We’ll only know for sure if (when?) the sector pulls back.In the […]
Fits and starts in developing a revolutionary new inhaled insulin have meant that Al Mann’s MannKind has had more than its fair share of pops and drops over the past few years. MannKind won FDA approval for Afrezza last summer and announced its commercial launch earlier this month . The news has investors wondering if now is a good time […]
Source: Flickr user epSos .de .There might not be a bell that will ring to alert investors when they have put their money in the wrong biotech stock, but there are warning signals that can help them avoid owning the most dangerous biotech companies. Our Motley Fool contributors explain what these warning signals are and how to use them to […]
Dividend paying stocks are a staple in market-beating investment portfolios, but dividend investors don’t have very many options when it comes to investing in the biotechnology sector. Out of the largest biotechnology stocks, only Amgen has made the decision to reward investors with dividend payments.That’s likely frustrating to dividend investors. After all, biotech stocks like Gilead Sciences generate billions of […]
Nothing boosts the prospects of page hits on a blog – or funding of a grant proposal – like the phrase “big data.” Why are we enamored with “big data”? It’s not the magic bullet of management or policy: It’s made money for a few companies, but has backfired bigtime in the arenas of national security (NSA surveillance scandals) and […]
